Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia

Croucher, PJP; Ridinger, M; Becker, PS; Lin, TL; Silberman, SL; Wang, ES; Zeidan, AM

Zeidan, AM (通讯作者)，Yale Univ, 333 Cedar St,POB 208028, New Haven, CT 06520 USA.;Zeidan, AM (通讯作者)，Yale Canc Ctr, 333 Cedar St,POB 208028, New Haven, CT 06520 USA.

ANNALS OF HEMATOLOGY, 2023; ():

Abstract

PLK1 is overexpressed in acute myeloid leukemia (AML). A phase 1b trial of the PLK1 inhibitor onvansertib (ONV) combined with decitabine (DAC) demonst......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索